Table 1 Clinical characteristics of SARP patients
Clinical characteristic | Total (N = 66) | Deceased patients (n = 31) | Surviving patients (n = 35) | P value |
|---|---|---|---|---|
Age (years) | Â | Â | Â | Â |
Median (IQR) | 64.50 (63.00–67.00) | 66.00 (62.00–71.00) | 64.00 (62.00–67.00) | 0.175 |
Gender | Â | Â | Â | 0.263 |
Male | 49.00 (74.24%) | 25.00 (80.65%) | 24.00 (68.57%) | |
Female | 17.00 (25.76%) | 6.00 (19.35%) | 11.00 (31.43%) | |
ECOG PS | Â | Â | Â | 0.948 |
0–1 | 53.00 (80.30%) | 25.00 (80.65%) | 28.00 (80.00%) | |
2 | 13.00 (19.70%) | 6.00 (19.35%) | 7.00 (20.00%) | |
COPD | Â | Â | Â | 0.896 |
Yes | 25.00 (37.88%) | 12.00 (38.71%) | 13.00 (37.14%) | |
No | 41.00 (62.12%) | 19.00 (61.29%) | 22.00 (62.86%) | |
Smoking (pack-year) | Â | Â | Â | 0.828 |
< 20 | 35.00 (53.03%) | 16.00 (51.61%) | 19.00 (54.29%) | |
≥ 20 | 31.00 (46.97%) | 15.00 (48.39%) | 16.00 (45.71%) | |
Diabetes | Â | Â | Â | 0.855 |
Yes | 8.00 (12.12%) | 4.00 (12.90%) | 4.00 (11.43%) | |
No | 58.00 (87.88%) | 27.00 (87.10%) | 31.00 (88.57%) | |
Histology | Â | Â | Â | Â |
SCC | 38.00 (57.58%) | 18.00 (58.06%) | 20.00 (57.14%) | 0.997 |
AC | 13.00 (19.70%) | 6.00 (19.35%) | 7.00 (20.00%) | |
Other | 15.00 (22.72%) | 7.00 (22.58%) | 8.00 (22.86%) | |
Ki-67 | Â | Â | Â | 0.367 |
Median (IQR) | 60.00 (40.00–60.00) | 40.00 (0.00–60.00) | 65.00 (40.00–80.00) | |
Lobe | Â | Â | Â | Â |
Right middle | 8.00 (12.12%) | 2.00 (6.45%) | 6.00 (17.14%) | 0.342 |
Right upper | 22.00 (33.33%) | 10.00 (32.26%) | 12.00 (34.29%) | 0.862 |
Right lower | 16.00 (24.24%) | 9.00 (29.03%) | 6.00 (17.14%) | 0.250 |
Left upper | 15.00 (22.72%) | 7.00 (22.58%) | 8.00 (22.86%) | 0.979 |
Left lower | 6.00 (9.09%) | 3.00 (9.68%) | 3.00 (8.57%) | 1.000 |
AJCC 8 Stage | Â | Â | Â | 0.728 |
II | 14.00 (21.21%) | 6.00 (19.35%) | 8.00 (22.86%) | |
III | 52.00 (78.79%) | 25.00 (80.65%) | 27.00 (77.14%) | |
Prior lung cancer surgery | Â | Â | Â | 0.454 |
Yes | 20.00 (30.30%) | 8.00 (25.81%) | 12.00 (34.29%) | |
No | 46.000 (69.70%) | 23.00 (74.19%) | 23.00 (65.71%) | |
Chemotherapy | Â | Â | Â | 0.767 |
Concurrent chemotherapy | 50.00 (75.76%) | 24.00 (77.41%) | 26.00 (74.29%) | |
Sequential chemotherapy | 16.00 (24.24%) | 7.00 (22.58%) | 9.00 (25.71%) | |
RT dose received | Â | Â | Â | 0.127 |
40 or 58Â Gy | 24.00 (36.36%) | 10.00 (32.26%) | 14.00 (40.00%) | |
59–60 Gy | 33.00 (50.00%) | 19.00 (61.29%) | 14.00 (40.00%) | |
61–65 Gy | 9.00 (13.64%) | 2.00 (6.45%) | 7.00 (20.00%) |